Research programme: Interleukin 13 targeting protein therapeutics - Generate Biomedicines
Latest Information Update: 27 Dec 2023
At a glance
- Originator Generate Biomedicines
- Class Proteins
- Mechanism of Action Interleukin 13 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 27 Dec 2023 Early research in Immunological disorders in USA (unspecified route) (Generate Biomedicines pipeline, December 2023)